UBS Group
IBB icon

UBS Group’s iShares Biotechnology ETF IBB Stock Holding History

UBS Group’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137M Sell
814,290
-98,745
-11% -$16.9M 0.02% 818
2025
Q4 		$154M Sell
913,035
-178,014
-16% -$28.9M 0.03% 711
2025
Q3 		$158M Sell
1,091,049
-376,318
-26% -$51.4M 0.02% 715
2025
Q2 		$186M Buy
1,467,367
+52,237
+4% +$6.41M 0.03% 568
2025
Q1 		$181M Buy
1,415,130
+313,404
+28% +$42.5M 0.03% 565
2024
Q4 		$146M Buy
1,101,726
+223,227
+25% +$31.4M 0.03% 682
2024
Q3 		$128M Sell
878,499
-27,111
-3% -$3.92M 0.03% 611
2024
Q2 		$124M Sell
905,610
-530,425
-37% -$70.8M 0.03% 539
2024
Q1 		$197M Buy
1,436,035
+118,886
+9% +$16.2M 0.05% 371
2023
Q4 		$179M Sell
1,317,149
-103,434
-7% -$12.6M 0.05% 349
2023
Q3 		$174M Sell
1,420,583
-120,951
-8% -$15.4M 0.06% 322
2023
Q2 		$196M Buy
1,541,534
+181,338
+13% +$23.6M 0.07% 284
2023
Q1 		$176M Sell
1,360,196
-107,646
-7% -$14.1M 0.06% 286
2022
Q4 		$193M Sell
1,467,842
-68,282
-4% -$8.82M 0.07% 287
2022
Q3 		$180M Sell
1,536,124
-417,142
-21% -$51.8M 0.08% 262
2022
Q2 		$230M Sell
1,953,266
-52,530
-3% -$6.24M 0.09% 231
2022
Q1 		$261M Buy
2,005,796
+146,343
+8% +$19.1M 0.09% 239
2021
Q4 		$284M Sell
1,859,453
-78,580
-4% -$12.2M 0.08% 249
2021
Q3 		$313M Sell
1,938,033
-371,200
-16% -$62.5M 0.1% 208
2021
Q2 		$378M Buy
2,309,233
+87,588
+4% +$13.5M 0.12% 167
2021
Q1 		$334M Sell
2,221,645
-17,046
-0.8% -$2.71M 0.11% 191
2020
Q4 		$339M Sell
2,238,691
-3,654
-0.2% -$522K 0.11% 197
2020
Q3 		$304M Sell
2,242,345
-123,858
-5% -$16.8M 0.11% 185
2020
Q2 		$323M Buy
2,366,203
+535,280
+29% +$68.2M 0.14% 163
2020
Q1 		$197M Sell
1,830,923
-269,137
-13% -$31M 0.09% 212
2019
Q4 		$253M Sell
2,100,060
-34,370
-2% -$3.83M 0.09% 222
2019
Q3 		$212M Sell
2,134,430
-3,626,524
-63% -$380M 0.08% 235
2019
Q2 		$629M Buy
5,760,954
+1,679,761
+41% +$179M 0.24% 93
2019
Q1 		$456M Buy
4,081,193
+854,906
+26% +$93.8M 0.19% 127
2018
Q4 		$311M Sell
3,226,287
-382,189
-11% -$40.6M 0.14% 160
2018
Q3 		$440M Sell
3,608,476
-861,112
-19% -$101M 0.17% 136
2018
Q2 		$491M Buy
4,469,588
+1,537,624
+52% +$164M 0.21% 112
2018
Q1 		$313M Buy
2,931,964
+97,678
+3% +$10.8M 0.14% 173
2017
Q4 		$303M Buy
2,834,286
+1,070,325
+61% +$114M 0.12% 181
2017
Q3 		$196M Sell
1,763,961
-58,341
-3% -$6.24M 0.09% 227
2017
Q2 		$188M Sell
1,822,302
-320,028
-15% -$31.5M 0.1% 225
2017
Q1 		$209M Buy
2,142,330
+150,294
+8% +$14.4M 0.11% 203
2016
Q4 		$176M Buy
1,992,036
+495,741
+33% +$45.1M 0.1% 225
2016
Q3 		$144M Sell
1,496,295
-156,252
-9% -$14.9M 0.09% 249
2016
Q2 		$142M Buy
1,652,547
+265,632
+19% +$23.8M 0.09% 234
2016
Q1 		$121M Sell
1,386,915
-791,277
-36% -$70.8M 0.08% 245
2015
Q4 		$246M Sell
2,178,192
-918,030
-30% -$99.6M 0.16% 140
2015
Q3 		$313M Buy
3,096,222
+631,134
+26% +$75.7M 0.22% 93
2015
Q2 		$303M Buy
2,465,088
+16,323
+0.7% +$1.95M 0.2% 105
2015
Q1 		$280M Sell
2,448,765
-1,120,956
-31% -$124M 0.19% 121
2014
Q4 		$361M Buy
+3,569,721
New +$347M 0.25% 79

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group's IBB Position: Q1 2026 in Review

UBS Group reduced its iShares Biotechnology ETF (IBB) stake by 11% in Q1 2026, selling an estimated $16.9M and leaving 814,290 shares worth $137M. The position accounts for 0.02% of the portfolio, ranked #818.

UBS Group first reported a position in IBB in Q4 2014 and has held it in 46 quarters since. The position peaked at $629M in Q2 2019. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • UBS Group held 814,290 shares of iShares Biotechnology ETF worth $137M as of Q1 2026.
  • UBS Group sold 98,745 iShares Biotechnology ETF shares in Q1 2026, an estimated $16.9M.
  • iShares Biotechnology ETF made up 0.02% of UBS Group's portfolio in Q1 2026, its #818 holding.
  • UBS Group first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's iShares Biotechnology ETF position peaked at $629M in Q2 2019.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.